We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
-12.51%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$385M
AUM Growth
-$193M
Cap. Flow
-$99.2M
Cap. Flow %
-25.79%
Top 10 Hldgs %
86.1%
Holding
23
New
–
Increased
3
Reduced
13
Closed
3

Top Buys

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$4.01M
2
MZOR
Mazor Robotics Ltd.
MZOR
+$958K
3
OPK icon
Opko Health
OPK
+$1.83K

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$34.9M
2
PGEN icon
Precigen
PGEN
+$16.8M
3
WBMD
WebMD Health Corp.
WBMD
+$11.5M
4
NXTM
NxStage Medical Inc.
NXTM
+$9.99M
5
AXDX
Accelerate Diagnostics
AXDX
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 95.33%
2 Miscellaneous 4.31%
3 Consumer Staples 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXDX
1
DELISTED
Accelerate Diagnostics
AXDX
$72.4M 18.82%
503,775
-60,579
-11% -$8.55M
QDEL icon
2
QuidelOrtho
QDEL
$808M
$44.4M 11.55%
2,573,554
-222,730
-8% -$3.73M
OPK icon
3
Opko Health
OPK
$1.17B
$40.7M 10.57%
3,914,000
+200
+0% +$1.83K
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
$40.4M 10.5%
2,694,636
-596,365
-18% -$9.99M
MZOR
5
DELISTED
Mazor Robotics Ltd.
MZOR
$36.2M 9.41%
2,909,566
+92,931
+3% +$958K
TSRO
6
DELISTED
TESARO, Inc.
TSRO
$28.2M 7.34%
640,966
+100,000
+18% +$4.01M
PACB icon
7
Pacific Biosciences
PACB
$404M
$26.6M 6.92%
3,312,089
-344,342
-9% -$3.39M
ARAY icon
8
Accuray
ARAY
$29.9M
$14.8M 3.84%
2,553,218
-331,087
-11% -$1.83M
BIOL
9
DELISTED
Biolase, Inc.
BIOL
$13.8M 3.59%
842
– –
PGEN icon
10
Precigen
PGEN
$2.45B
$13.7M 3.56%
407,363
-533,615
-57% -$16.8M
VRML
11
DELISTED
Vermillion, Inc.
VRML
$12.7M 3.3%
8,624,225
– –
HNSN
12
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$11.7M 3.04%
4,491,820
– –
AMRN
13
Amarin Corp
AMRN
$291M
$8.9M 2.32%
290,940
-41,350
-12% -$1.23M
AGEN
14
Agenus
AGEN
$312M
$7.83M 2.04%
95,912
-50,093
-34% -$3.38M
TTHI
15
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$4.89M 1.27%
3,817,972
-90,489
-2% -$105K
CFRX
16
DELISTED
ContraFect Corporation
CFRX
$4.02M 1.05%
1,478
– –
BIIB icon
17
Biogen
BIIB
$32.1B
$1.75M 0.46%
6,723
-1,000
-13% -$264K
YTEN
18
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$1.38M 0.36%
76
-21
-22% -$311K
VANI icon
19
Vivani Medical
VANI
$115M
$245K 0.06%
2,117
-6,360
-75% -$732K
TCRT icon
20
Alaunos Therapeutics
TCRT
$3.84M
$49K 0.01%
44
-833
-95% -$853K
CMRX
21
DELISTED
Chimerix, Inc.
CMRX
– –
-736,421
Closed -$6.59M
ACOR
22
DELISTED
Acorda Therapeutics
ACOR
– –
-6,799
Closed -$34.9M
WBMD
23
DELISTED
WebMD Health Corp.
WBMD
– –
-238,103
Closed -$11.5M

Similar funds

EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM
CWA
Clearview Wealth Advisors Salem, Oregon $158M AUM 14.25% 1-Year Est. Return
CNFG
Creegan & Nassoura Financial Group Portsmouth, New Hampshire $154M AUM 17.18% 1-Year Est. Return
VA
Verus Advisory Seattle, Washington $153M AUM
PSB
Passumpsic Savings Bank St. Johnsbury, Vermont $183M AUM

Oracle Investment Management's Q1 2016 Portfolio in Review

As of Q1 2016, Oracle Investment Management held 23 positions worth $385M, down 33% from $577M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Oracle Investment Management withdrew a net $99.2M in Q1 2016, closing 3 positions and reducing 13 holdings. Its most notable exit was Acorda Therapeutics, an estimated $34.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Oracle Investment Management added an estimated $4.01M to TESARO, Inc..

  • Oracle Investment Management added most to TESARO, Inc. in Q1 2016, an estimated $4.01M increase.
  • Oracle Investment Management's biggest Q1 2016 reduction was Precigen, cutting an estimated $16.8M.
  • Oracle Investment Management fully exited Acorda Therapeutics in Q1 2016, selling an estimated $34.9M.
  • Oracle Investment Management's ten largest holdings make up 86% of its $385M portfolio in Q1 2016.
  • Oracle Investment Management opened 0 new positions and closed 3 in Q1 2016.
  • Oracle Investment Management's portfolio value fell 33% quarter-over-quarter to $385M.

Based on Oracle Investment Management's 13F filing for Q1 2016, filed 16 May 2016.